ArticleFrontiers in pharmacology2022
Intestinal anti-inflammatory and visceral analgesic effects of a
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06639126 (Intervention Study Focused on the Intestinal Microbiome to Evaluate the Impact of a Wild Thyme Extract), which is not on this map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Intervention Study Focused on the Intestinal Microbiome to Evaluate the Impact of a Wild Thyme Extract (Thymus Serpyllum) Extract With Anti-inflammatory and Metabolic Properties Against Functional Gastrointestinal Disorders.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Wild thyme (Frontiers in nutrition · 2024Pooled it
- Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines.Nutrients · 2026Review
- Article
- Extracellular vesicles from Li-Qi-Yang-Yin formula attenuate LPS-stimulated inflammatory injury in human colonic epithelial cellsFrontiers in medicine · 2026Article
- A reciprocal interaction between L-lysine andiMetaOmics · 2025Article
- Implications of nociceptor receptors and immune modulation: emerging therapeutic targets for autoimmune diseases.Inflammopharmacology · 2025Review
- Therapeutic Potential of Flavonoids and Flavonoid-Rich Compounds in Irritable Bowel Syndrome.Drug design, development and therapy · 2025Review
- Bile acids and gut microbiota: interactions and impacts on polycystic ovary syndrome.Frontiers in microbiomes · 2025Review
- Zuojinwan ameliorates depressive-like behavior and gastrointestinal dysfunction in mice by modulating the FXR-bile acid-gut microbiota pathway.Frontiers in microbiology · 2025Article
- Supplementation withFrontiers in immunology · 2024Article
- Toll-like receptor 4 plays a vital role in irritable bowel syndrome: a scoping review.Frontiers in immunology · 2024Article
- Effects ofInternational journal of molecular sciences · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.